Pan Cancer T

Pan Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

Pan Cancer T develops natural affinity TCR T cell therapies against unique and proprietary intracellular targets expressed by multiple solid tumors.

Unique targets

div1

  • 30 intracellular targets
  • First-in class for adoptive T cell therapy
  • Restricted to tumor cells
  • Immunogenic and shared amongst large patient cohorts

Fit TCR T cells

div1

  • Rigorous efficacy and safety screening
  • High specificity and no cross-reactive TCR
  • Natural affinity and effective
  • Fit T cells with no signs of early exhaustion

Outsmart T cell-resistant tumors

div1

  • Extensive immune profiling of tumors
  • Guided selection of anti-TME modulators
  • Translated into T cell engineering
  • Maximized accessibility of treatment

Our latest news